KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pfizer (PFE) Other Operating Expenses (2016 - 2017)

Pfizer has reported Other Operating Expenses over the past 8 years, most recently at -$6.7 billion for Q4 2017.

  • Quarterly Other Operating Expenses rose 12.65% to -$6.7 billion in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$6.7 billion through Sep 2018, up 71.67% year-over-year, with the annual reading at -$22.7 billion for FY2017, 6.78% up from the prior year.
  • Other Operating Expenses was -$6.7 billion for Q4 2017 at Pfizer, down from -$5.4 billion in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $1.1 billion in Q2 2013 and troughed at -$7.9 billion in Q4 2015.
  • The 5-year median for Other Operating Expenses is -$5.3 billion (2017), against an average of -$3.9 billion.
  • Year-over-year, Other Operating Expenses soared 255.52% in 2013 and then tumbled 9796.23% in 2015.
  • A 5-year view of Other Operating Expenses shows it stood at $18.0 million in 2013, then skyrocketed by 194.44% to $53.0 million in 2014, then plummeted by 14983.02% to -$7.9 billion in 2015, then increased by 2.69% to -$7.7 billion in 2016, then increased by 12.65% to -$6.7 billion in 2017.
  • Per Business Quant, the three most recent readings for PFE's Other Operating Expenses are -$6.7 billion (Q4 2017), -$5.4 billion (Q4 2017), and -$5.3 billion (Q3 2017).